返回
Bristol-Myers Squibb Co（BMY）價格
BMY 股價走勢圖
BMY 收益
Bristol-Myers Squibb Co
$54.22
-1.88%
$-1.03
收盤價：Jan 20, 16:00:00 GMT-5
$54.29
0.12%
$0.07
盤後：Jan 20, 20:00:00 GMT-5
B-
最終分數
關鍵數據
前收市價
$55.26
開盤價
$54.53
當日範圍
$53.88 - $54.9
52週區間
$42.52 - $63.33
交易量
10.7M
平均成交量
15.4M
每股盈餘 (TTM)
2.96
股息收益率
4.59%
市值
$110.5B
什麼是 BMY？
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.